TOP TEN perturbations for 1552923_a_at (Homo sapiens)
Organism: Homo sapiens
Gene: 1552923_a_at
Selected probe(set): 1552924_a_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 1552923_a_at (1552924_a_at) across 6673 perturbations tested by GENEVESTIGATOR:
B-CLL study 11 (rolipram) / rolipram study 4 (normal B-cell; 20uM)
Relative Expression (log2-ratio):4.1984253Number of Samples:4 / 4
Experimental | B-CLL study 11 (rolipram) |
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:--- | |
Control | rolipram study 4 (normal B-cell; 20uM) |
MACS purified resting B-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:--- |
B-CLL study 11 (rolipram) / rolipram study 4 (normal T-cell; 20uM)
Relative Expression (log2-ratio):4.190645Number of Samples:4 / 4
Experimental | B-CLL study 11 (rolipram) |
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. ATC code:--- | |
Control | rolipram study 4 (normal T-cell; 20uM) |
MACS purified T-cells from healthy donor peripheral blood treated with rolipram (20 uM, cyclic nucleotide phosphodiesterase (PDE4) inhibitor) for 4 hours. ATC code:--- |
B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal B-cell sample
Relative Expression (log2-ratio):3.271348Number of Samples:4 / 4
Experimental | B-CLL study 11 (DMSO) |
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. | |
Control | vehicle (DMSO) treated normal B-cell sample |
MACS purified resting B-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours. |
B-CLL study 11 (DMSO) / vehicle (DMSO) treated normal T-cell sample
Relative Expression (log2-ratio):3.2165422Number of Samples:4 / 4
Experimental | B-CLL study 11 (DMSO) |
Peripheral blood mononuclear cells (PBMCs) obtained from chronic lymphocytic leukemia (CLL) patients and in vitro treated with vehicle (DMSO) for 4 hours. PBMCs’ samples contained 90% CD19+ CD5+ B lineage CLL cells (B-CLL). Inclusion criteria: untreated CLL patients or at least 1 month after chemotherapy. Exclusion criteria: patients with active infections or other serious medical conditions or with white blood cell (WBC) counts of 15,000/l. | |
Control | vehicle (DMSO) treated normal T-cell sample |
MACS purified T-cells from healthy donor peripheral blood treated with vehicle (DMSO) for 4 hours. |
CML study 1 / B-CLL study 5
Relative Expression (log2-ratio):-2.4876986Number of Samples:75 / 441
Experimental | CML study 1 |
Bone marrow samples of patients with chronic myeloid leukemia (CML). | |
Control | B-CLL study 5 |
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL). |
precursor-B-ALL study 1 (t(1;19)(q23,q13)) / normal bone marrow sample
Relative Expression (log2-ratio):2.4503298Number of Samples:36 / 74
Experimental | precursor-B-ALL study 1 (t(1;19)(q23,q13)) |
Bone marrow samples of patients with precursor B-ALL (t(1;19)(q23,q13)/E2A-PBX1). | |
Control | normal bone marrow sample |
Non-leukemic and healthy bone marrow sample. |
B-CLL study 5 / normal bone marrow sample
Relative Expression (log2-ratio):2.324314Number of Samples:441 / 74
Experimental | B-CLL study 5 |
Bone marrow samples of patients with B-cell chronic lymphocytic leukemia (B-CLL). | |
Control | normal bone marrow sample |
Non-leukemic and healthy bone marrow sample. |
precursor-B-ALL study 2 (E2A-PBX1) / precursor-B-ALL study 2 (hyperdiploid)
Relative Expression (log2-ratio):2.2966013Number of Samples:2 / 27
Experimental | precursor-B-ALL study 2 (E2A-PBX1) |
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Dutch Childhood Oncology Group (DCOG). | |
Control | precursor-B-ALL study 2 (hyperdiploid) |
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL (hyperdiploidy). Patients were part of the Dutch Childhood Oncology Group (DCOG). |
precursor-B-ALL study 2 (E2A-PBX1) / precursor-B-ALL study 2 (TEL-AML1)
Relative Expression (log2-ratio):2.011427Number of Samples:2 / 21
Experimental | precursor-B-ALL study 2 (E2A-PBX1) |
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Dutch Childhood Oncology Group (DCOG). | |
Control | precursor-B-ALL study 2 (TEL-AML1) |
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(12;21)(p13,q22)/TEL-AML1]. Patients were part of the Dutch Childhood Oncology Group (DCOG). |
precursor-B-ALL study 2 (MLL-rearranged) / precursor-B-ALL study 2 (E2A-PBX1)
Relative Expression (log2-ratio):-2.0010967Number of Samples:4 / 2
Experimental | precursor-B-ALL study 2 (MLL-rearranged) |
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(v;11q23)/MLL rearranged]. Patients were part of the Dutch Childhood Oncology Group (DCOG). | |
Control | precursor-B-ALL study 2 (E2A-PBX1) |
Peripheral blood and bone marrow samples of pediatric patients with precursor B-ALL [t(1;19)(q23;p13.3)/E2A PBX1 (TCF3 PBX1)]. Patients were part of the Dutch Childhood Oncology Group (DCOG). |